Xtx Topco LTD Exelixis, Inc. Transaction History

Xtx Topco LTD

$1.12 Billion
Q2 2024

A detailed history of Xtx Topco LTD transactions in Exelixis, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 13,748 shares of EXEL stock, worth $363,497. This represents 0.03% of its overall portfolio holdings.

Number of Shares

13,748

Holding current value

$363,497

% of portfolio

0.03%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$20.34 - $23.73 $279,634 - $326,240	13,748 New	13,748 $308,000
Q4 2023 Feb 13, 2024	SELL	$19.25 - $24.13 $110,649 - $138,699	-5,748 Reduced 32.6%	11,882 $285,000
Q3 2023 Nov 13, 2023	SELL	$19.04 - $22.74 $120,827 - $144,308	-6,346 Reduced 26.47%	17,630 $385,000
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $435,643 - $491,028	23,976 New	23,976 $458,000
Q4 2022 Feb 14, 2023	SELL	$14.96 - $17.39 $5,071 - $5,895	-339 Reduced 1.51%	22,128 $354,000
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $352,282 - $500,340	22,467 New	22,467 $352,000
Q1 2022 May 13, 2022	SELL	$17.03 - $22.67 $201,345 - $268,027	-11,823 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$15.84 - $21.88 $187,276 - $258,687	11,823 New	11,823 $216,000
Q2 2021 Aug 12, 2021	SELL	$17.95 - $25.56 $331,015 - $471,351	-18,441 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$20.53 - $25.22 $378,593 - $465,082	18,441 New	18,441 $417,000

Others Institutions Holding EXEL

# of Institutions

460

Shares Held

240M

Call Options Held

2.04M

Put Options Held

1.29M

Black Rock Inc. New York, NY

33.5M
Shares

$886 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

29.7M
Shares

$784 Million
0.01% of portfolio
Farallon Capital Management LLC San Francisco, CA

27.1M
Shares

$717 Million
2.95% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

15.2M
Shares

$401 Million
0.6% of portfolio
State Street Corp Boston, MA

12.6M
Shares

$333 Million
0.01% of portfolio

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $8.51B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account